Literature DB >> 8001348

African horse sickness virus structure.

P Roy1, P P Mertens, I Casal.   

Abstract

African horse sickness virus (AHSV), of which there are nine serotypes (AHSV-1, -2, etc.), is a member of Orbivirus genus within the Reoviridae family. Both in morphology and molecular constituents AHSV particles are comparable to those of bluetongue virus (BTV), the prototype virus of the genus. The two viruses have seven structural proteins (VP1-7) organized in two layered capsid. The outer capsid is composed of VP2 and VP5. The inner capsid, or core, is composed of two major proteins, VP3 and VP7, and three minor proteins, VP1, VP4 and VP6. Within the core is the virus genome. This genome consists of 10 double-stranded (ds)RNA segments of different sizes, three large, designated L1-L3, three medium, M4-M6, and four small, S7-S10. In addition to the seven structural proteins that are coded by seven of the RNA species, four non-structural proteins, NS1, NS2, NS3 and NS3A, are coded by three RNA segments, M5, S8 and S10. The two smallest proteins (NS3 and NS3A) are synthesized by the S10 RNA segment, probably from different in-frame translation initiation codons. Nucleotide sequences of eight RNA segments (L2, L3, M4, M5, M6, S7, S8 and S10) and the predicted amino acid sequences of the encoded gene products are also available, mainly representing one serotype, AHSV-4. In this review the properties of the AHSV genes and gene products are discussed. The sequence and hybridization analyses of the different AHSV dsRNA segments indicate that the segments that code for the core proteins, as well as those that code for NS1 and NS2 proteins, are highly conserved between the different virus serotypes. However, the RNA encoding NS3 and NS3A, and the two segments encoding the outer capsid proteins, are more variable between the AHSV serotypes. A close phylogenetic relationship between AHSV, BTV and epizootic haemorrhagic disease virus (EHDV), three Culicoides-transmitted orbiviruses, has been revealed when the equivalent sequences of genes and gene products are compared. Recently, the four major AHSV capsid proteins have been expressed using recombinant baculoviruses. Biochemically and antigenically these proteins are similar to the authentic proteins. Since the AHSV VP7 protein is highly conserved among the different serotypes, it has been utilized as a diagnostic reagent. The expressed VP7 protein has also been purified to homogeneity and crystallized for three-dimensional X-ray analysis.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001348     DOI: 10.1016/0147-9571(94)90046-9

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  15 in total

1.  Structural insight into African horsesickness virus infection.

Authors:  Violeta Manole; Pasi Laurinmäki; Wouter Van Wyngaardt; Christiaan A Potgieter; Isabella M Wright; Gert J Venter; Alberdina A van Dijk; B Trevor Sewell; Sarah J Butcher
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Serologic markers in early stages of African horse sickness virus infection.

Authors:  J L Martínez-Torrecuadrada; M Díaz-Laviada; P Roy; C Sánchez; C Vela; J M Sánchez-Vizcaíno; J I Casal
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

3.  A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Authors:  Javier Castillo-Olivares; Eva Calvo-Pinilla; Isabel Casanova; Katarzyna Bachanek-Bankowska; Rachael Chiam; Sushila Maan; Jose Maria Nieto; Javier Ortego; Peter Paul Clement Mertens
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

4.  Serotype specific primers and gel-based RT-PCR assays for 'typing' African horse sickness virus: identification of strains from Africa.

Authors:  Narender S Maan; Sushila Maan; Kyriaki Nomikou; Manjunatha N Belaganahalli; Katarzyna Bachanek-Bankowska; Peter P C Mertens
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

5.  Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine.

Authors:  Susan J Dennis; Ann E Meyers; Alan J Guthrie; Inga I Hitzeroth; Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2017-08-01       Impact factor: 9.803

6.  The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.

Authors:  Eva Calvo-Pinilla; Simon Gubbins; Peter Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2018-04-18       Impact factor: 5.970

7.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

8.  Characterising Non-Structural Protein NS4 of African Horse Sickness Virus.

Authors:  Lizahn Zwart; Christiaan A Potgieter; Sarah J Clift; Vida van Staden
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

9.  A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.

Authors:  Mine Aksular; Eva Calvo-Pinilla; Alejandro Marín-López; Javier Ortego; Adam C Chambers; Linda A King; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2018-10-08       Impact factor: 3.641

Review 10.  Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.

Authors:  Elizabeth A Clemmons; Kendra J Alfson; John W Dutton
Journal:  Animals (Basel)       Date:  2021-07-08       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.